Allied Market Research

2025

Japan Orphan Drugs Market

Japan Orphan Drugs Market, by DISEASE TYPE (ONCOLOGIC DISEASES, METABOLIC DISEASES, HEMATOLOGIC AND IMMUNOLOGIC DISEASES, INFECTIOUS DISEASES, NEUROLOGIC DISEASES, OTHER RARE DISEASES) and, by INDICATION (NON-HODGKIN LYMPHOMA, ACUTE MYELOID LEUKEMIA, CYSTIC FIBROSIS, GLIOMA, PANCREATIC CANCER, OVARIAN CANCER, MULTIPLE MYELOMA, DUCHENNE MUSCULAR DYSTROPHY, GRAFT VS HOST DISEASE, RENAL CELL CARCINOMA, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals

Select an option
Author's: | Roshan Deshmukh
Publish Date:

Get Sample to Email

Japan Orphan Drugs Market Report Highlights

Aspects Details
icon_5
By DISEASE TYPE
  • ONCOLOGIC DISEASES
  • METABOLIC DISEASES
  • HEMATOLOGIC AND IMMUNOLOGIC DISEASES
  • INFECTIOUS DISEASES
  • NEUROLOGIC DISEASES
  • OTHER RARE DISEASES
icon_6
By INDICATION
  • NON-HODGKIN LYMPHOMA
  • ACUTE MYELOID LEUKEMIA
  • CYSTIC FIBROSIS
  • GLIOMA
  • PANCREATIC CANCER
  • OVARIAN CANCER
  • MULTIPLE MYELOMA
  • DUCHENNE MUSCULAR DYSTROPHY
  • GRAFT VS HOST DISEASE
  • RENAL CELL CARCINOMA
  • Others
icon_7
Key Market Players

Merck KGaA, Kyowa Hakko Kirin Co., Ltd., Eisai Co., Ltd., Daiichi Sankyo Company, Limited, Takeda Pharmaceutical Company Limited, Pfizer, Inc., Otsuka Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Chugai Pharmaceutical Co., Ltd., Astellas Pharma Inc.

Loading Table Of Content...

Japan Orphan Drugs Market

Global Opportunity Analysis and Industry Forecast, 2023-2032